Vivozon Pharmaceutical Co., Ltd. (KOSDAQ: 082800)
South Korea
· Delayed Price · Currency is KRW 9,110.00
-510.00 (-5.30%)
Dec 20, 2024, 9:00 AM KST
Vivozon Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 87,275 | 71,318 | 51,564 | 57,560 | 43,592 | 43,974 | Upgrade
|
| Other Revenue | - | - | - | -0 | - | 978.75 | Upgrade
|
| Revenue | 87,275 | 71,318 | 51,564 | 57,560 | 43,592 | 44,953 | Upgrade
|
| Revenue Growth (YoY) | 37.32% | 38.31% | -10.42% | 32.04% | -3.03% | -2.28% | Upgrade
|
| Cost of Revenue | 43,469 | 39,997 | 30,128 | 37,921 | 36,461 | 41,654 | Upgrade
|
| Gross Profit | 43,806 | 31,321 | 21,437 | 19,639 | 7,130 | 3,299 | Upgrade
|
| Selling, General & Admin | 34,631 | 25,082 | 23,031 | 28,627 | 10,427 | 4,038 | Upgrade
|
| Research & Development | 3,524 | 2,541 | 1,927 | 3,935 | 2,870 | 380.5 | Upgrade
|
| Operating Expenses | 39,523 | 26,611 | 31,243 | 39,253 | 15,169 | 6,088 | Upgrade
|
| Operating Income | 4,284 | 4,709 | -9,806 | -19,615 | -8,039 | -2,789 | Upgrade
|
| Interest Expense | -2,151 | -2,904 | -5,271 | -7,297 | -10,792 | -7,560 | Upgrade
|
| Interest & Investment Income | - | 345.14 | 840.79 | 909.59 | 1,274 | 432.33 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -691.35 | - | 963.27 | Upgrade
|
| Currency Exchange Gain (Loss) | -59.86 | -6.07 | 125.03 | 999.14 | -774.58 | 203.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -605.6 | -43.59 | -940 | -402.96 | 1,782 | 17.53 | Upgrade
|
| EBT Excluding Unusual Items | 1,468 | 2,101 | -15,051 | -26,097 | -16,549 | -8,733 | Upgrade
|
| Gain (Loss) on Sale of Investments | -3,683 | -3,633 | -4,842 | 69.4 | -3,621 | -9,279 | Upgrade
|
| Gain (Loss) on Sale of Assets | -639.94 | -596.57 | -102.92 | -229.9 | 337.98 | -2,156 | Upgrade
|
| Asset Writedown | -29.21 | -29.21 | -5,252 | -49,590 | -23,990 | -2,472 | Upgrade
|
| Other Unusual Items | - | - | -92.74 | - | - | - | Upgrade
|
| Pretax Income | -2,885 | -2,158 | -25,342 | -75,848 | -43,822 | -22,639 | Upgrade
|
| Income Tax Expense | 55.27 | 55.27 | 1,509 | -4,833 | 263.27 | - | Upgrade
|
| Earnings From Continuing Operations | -2,940 | -2,214 | -26,851 | -71,015 | -44,085 | -22,639 | Upgrade
|
| Earnings From Discontinued Operations | 227.4 | -1,143 | -13,827 | - | - | -6,368 | Upgrade
|
| Net Income to Company | -2,713 | -3,357 | -40,677 | -71,015 | -44,085 | -29,006 | Upgrade
|
| Minority Interest in Earnings | - | - | 771.55 | 1,558 | 330.6 | 1,008 | Upgrade
|
| Net Income | -2,713 | -3,357 | -39,906 | -69,457 | -43,754 | -27,998 | Upgrade
|
| Net Income to Common | -2,713 | -3,357 | -39,906 | -69,457 | -43,754 | -27,998 | Upgrade
|
| Shares Outstanding (Basic) | 47 | 48 | 44 | 33 | 26 | 21 | Upgrade
|
| Shares Outstanding (Diluted) | 47 | 48 | 44 | 33 | 26 | 21 | Upgrade
|
| Shares Change (YoY) | -0.49% | 9.69% | 33.41% | 24.52% | 24.63% | 65.66% | Upgrade
|
| EPS (Basic) | -57.24 | -70.35 | -917.27 | -2129.90 | -1670.65 | -1332.34 | Upgrade
|
| EPS (Diluted) | -57.36 | -70.35 | -917.27 | -2130.00 | -1670.65 | -1332.34 | Upgrade
|
| Free Cash Flow | -589.9 | -1,532 | -9,814 | -27,608 | 3,755 | -4,106 | Upgrade
|
| Free Cash Flow Per Share | -12.45 | -32.10 | -225.59 | -846.59 | 143.39 | -195.38 | Upgrade
|
| Gross Margin | 50.19% | 43.92% | 41.57% | 34.12% | 16.36% | 7.34% | Upgrade
|
| Operating Margin | 4.91% | 6.60% | -19.02% | -34.08% | -18.44% | -6.20% | Upgrade
|
| Profit Margin | -3.11% | -4.71% | -77.39% | -120.67% | -100.37% | -62.28% | Upgrade
|
| Free Cash Flow Margin | -0.68% | -2.15% | -19.03% | -47.96% | 8.62% | -9.13% | Upgrade
|
| EBITDA | 7,824 | 7,937 | -6,162 | -14,062 | -5,860 | -672.11 | Upgrade
|
| EBITDA Margin | 8.96% | 11.13% | -11.95% | -24.43% | -13.44% | -1.50% | Upgrade
|
| D&A For EBITDA | 3,540 | 3,228 | 3,643 | 5,552 | 2,179 | 2,117 | Upgrade
|
| EBIT | 4,284 | 4,709 | -9,806 | -19,615 | -8,039 | -2,789 | Upgrade
|
| EBIT Margin | 4.91% | 6.60% | -19.02% | -34.08% | -18.44% | -6.20% | Upgrade
|
| Advertising Expenses | - | 617.32 | 1,688 | 4,419 | 1,037 | 3.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.